When Antibiotics Fail: AMR, Cystic Fibrosis and the Potential of Phage Therapy
Antimicrobial resistance is progressively reducing the effectiveness of drugs on which modern medicine depends. A CNN investigation published on September 9, 2026 examines the consequences through patients affected by severe infections that became increasingly difficult to treat, while also discussing bacteriophage therapy as an experimental strategy for bacterial infections resistant to conventional antibiotics.
The global burden is already substantial. According to the World Health Organization, bacterial antimicrobial resistance was associated with more than 4.7 million deaths worldwide in 2021, including approximately 1.14 million deaths directly attributable to resistance. Current modelling projects around 39 million deaths directly attributable to bacterial AMR cumulatively between 2025 and 2050 if current trends continue, rather than 39 million deaths in a single year.
Resistance develops through microbial evolution and selection. Bacteria can acquire resistance through mutations or through genetic material exchanged between microorganisms, while antimicrobial exposure preferentially eliminates susceptible populations and allows resistant organisms to survive and expand. Excessive or inappropriate antimicrobial use accelerates this process, but inadequate infection prevention, limited diagnostic capacity and insufficient access to appropriate medicines and vaccines also contribute to the global problem.
CNN illustrates the clinical consequences through the story of Obelix Liauw in Indonesia. Soon after birth, Obelix developed severe vomiting and diarrhoea, required neonatal intensive care and was eventually diagnosed with congenital short bowel syndrome, a rare condition that prevented normal absorption of nutrients and resulted in prolonged hospitalization. During this period he developed sepsis, while laboratory testing indicated that the antibiotics physicians hoped to use were ineffective against the infection.
Obelix died on February 12, 2020 at three months and two weeks of age. No autopsy was performed, meaning that antimicrobial resistance cannot be established retrospectively as the definitive cause of death, but his parents believe that resistance contributed to the inability to control the infection. The case illustrates why AMR becomes particularly dangerous in patients whose underlying disease, hospitalization or immune status already places them at high risk of invasive bacterial infection.
The problem is especially important in diseases requiring repeated antimicrobial treatment over many years. Cystic fibrosis is one example because chronic respiratory infection can expose bacterial populations to repeated courses of antibiotics, creating sustained selective pressure and increasing the probability that difficult-to-treat resistant populations will emerge and persist.
CNN focuses on the experience of Mallory Smith, who was diagnosed with cystic fibrosis at the age of three and later developed a Burkholderia cepacia infection. The infection resulted in nearly 70 hospitalizations, and by 2016 available antibiotic treatment was failing to eradicate it. Smith ultimately underwent a double lung transplant, but the infection persisted after transplantation and she died in November 2017 at the age of 25.
Burkholderia cepacia complex infections are particularly relevant to cystic fibrosis because members of this group can display extensive antimicrobial resistance and can establish persistent respiratory infections in susceptible patients. In Smith's case, the progressive loss of effective antibiotic options led her physicians to investigate an alternative antibacterial strategy based on bacteriophages.
Before her death, her medical team obtained authorization from the US Food and Drug Administration to administer experimental phage therapy. In the United States, individualized phage treatment has generally been accessed through investigational pathways such as emergency or single-patient expanded access rather than as an established routinely approved antimicrobial treatment.
Bacteriophages are viruses that infect bacteria rather than human cells. For therapeutic purposes, researchers are principally interested in lytic phages capable of recognizing a susceptible bacterium, replicating within it and producing progeny phages while causing bacterial lysis. This mechanism is fundamentally different from conventional antibiotic activity, meaning that bacterial resistance to an antibiotic does not automatically imply resistance to a bacteriophage.
Phage specificity creates a potential advantage because antibacterial activity can be directed toward the infecting bacterium while producing less broad disruption of unrelated bacterial populations. The same specificity is also a major translational limitation, because a phage active against one clinical isolate may have little or no activity against another strain belonging to the same bacterial species.
Individualized treatment can therefore require isolation of the patient's bacterial pathogen followed by susceptibility screening against a sufficiently diverse collection of bacteriophages. For uncommon or highly resistant organisms, identifying an active phage quickly enough for a critically ill patient can become one of the major practical barriers to treatment, a difficulty emphasized in the CNN investigation.
Phage therapy also cannot be evaluated solely from the ability of a phage to produce bacterial killing under laboratory conditions. The infection environment, bacterial physiological state, accessibility of the infected tissue, interactions with the immune system, emergence of phage-resistant bacterial variants and the pharmacokinetics of administered phages can all influence whether activity observed in vitro translates into clinically relevant bacterial control.
Chronic infections present additional difficulties because bacteria may persist in spatially protected populations and can change their physiology during long-term colonization. These biological differences help explain why a phage selected against an isolated bacterial strain cannot automatically be assumed to eradicate the corresponding infection in a patient.
CNN reports that Smith's mother, Diane Shader Smith, was told that post-mortem findings suggested that the phage treatment had begun acting against the infection, although it did not save her daughter's life. This observation should not be interpreted as evidence that phage therapy was clinically effective in this case, because compassionate-use treatment in a critically ill patient does not provide the controls necessary to establish causality or quantify efficacy.
Individual compassionate-use cases nevertheless provide information that can inform subsequent research. They can reveal whether particular administration strategies are feasible, identify adverse events, document changes in bacterial susceptibility and phage concentrations during treatment, and generate hypotheses that can later be investigated under standardized experimental or clinical conditions.
The safety of phage preparations also depends on manufacturing and purification rather than on the biological specificity of phages alone. Therapeutic preparations must control bacterial contaminants generated during phage production, while rapid destruction of Gram-negative bacteria can release inflammatory bacterial components such as endotoxin. CNN notes that phage therapy is not a universal solution and that additional evaluation is required before substantially broader clinical use.
The scientific development of phage therapy therefore requires several systems to function simultaneously. Large and well-characterized phage collections are needed to increase the probability of matching resistant clinical isolates, diagnostic laboratories must rapidly identify pathogens and their susceptibility, manufacturing platforms must provide suitably characterized material, and clinical trials must determine dosing, routes of administration and treatment schedules for defined infection types.
Phages are also unlikely to eliminate the need for antibiotics. A substantial area of current research instead concerns their use alongside antibiotics, because the two therapeutic classes target bacteria through different mechanisms and impose different evolutionary pressures. Whether a particular combination is beneficial must be demonstrated for the specific phage, bacterium, antibiotic and infection context rather than assumed from general principles.
The broader AMR problem also extends beyond hospitals and individual patients. Resistant organisms and antimicrobial-resistance genes can circulate between people, healthcare facilities, animals, food systems and environmental reservoirs, making prevention and surveillance essential components of antimicrobial policy. CNN quotes Xin Deng of City University of Hong Kong emphasizing that resistant bacteria circulate across countries, while the major difference between health systems lies in their capacity to prevent infections, diagnose them accurately and respond effectively.
The World Health Organization reports that approximately one in six laboratory-confirmed bacterial infections worldwide was resistant to antibiotic treatment in 2023. International targets include reducing deaths associated with bacterial AMR by 10% by 2030, strengthening diagnostic and surveillance capacity, improving infection prevention and controlling inappropriate antimicrobial use in both human health and food production.
More than 170 countries have now developed national AMR action plans, but implementation differs substantially between regions and health systems. The burden is particularly severe where diagnostic capacity, access to effective antibiotics, infection-control infrastructure and surveillance are limited, demonstrating that the development of new antimicrobial technologies cannot be separated from the question of whether health systems can actually deploy them.
Phage therapy occupies one part of this larger response. Its biological capacity to infect antibiotic-resistant bacteria provides a rational basis for therapeutic development, but routine clinical implementation requires substantially more than demonstrating bacterial lysis: phage-host matching, resistance monitoring, standardized production, quality control, appropriate regulatory pathways and controlled clinical evidence must all be integrated.
The cases described by CNN demonstrate why these questions are clinically relevant. When an infection progresses despite available antibiotics, the absence of an effective alternative can rapidly become life-threatening, particularly in immunocompromised patients and people with chronic bacterial infections. Developing phage therapy therefore means converting a naturally occurring bacterium-virus interaction into a reproducible antimicrobial treatment whose benefits, limitations and risks can be measured with the same scientific standards expected for other medicines.
Sources :
The primary journalistic source is Laura Sharman, CNN, He was their ‘little miracle.’ What happens when antibiotics stop working, published September 9, 2026. The report contains the cases of Obelix Liauw and Mallory Smith and the discussion of antimicrobial resistance and compassionate-use phage therapy. CNN — original article
AMR epidemiological figures were checked against the World Health Organization. WHO reports more than 4.7 million deaths associated with bacterial AMR in 2021 and approximately 1.14 million directly attributable deaths; the often-cited 39 million figure refers to projected cumulative attributable deaths between 2025 and 2050. WHO — Antimicrobial resistance fact sheet, July 2026
.png){kind=logo}
Comments
Post a Comment